This study is looking at whether adding precisely targeted radiation therapy, called Stereotactic Body Radiation Therapy (SBRT), to your usual drug treatment can help people with breast cancer that has spread (metastatic breast cancer). Specifically, it's for those with "oligometastatic" breast cancer, meaning the cancer has spread to only a few places, and one of those spots has worsened. You would continue your current drug therapy while receiving SBRT. Researchers want to see if this combination can stop the cancer from getting worse in other areas or spreading further. The study plans to include 46 participants and is looking for people aged 18 or older with biopsy-proven metastatic breast cancer, including ER+ (estrogen receptor positive) and HER2+ (human epidermal growth factor receptor 2 positive) types. Success will be measured by how long participants live without their cancer progressing, checked at 3 months after SBRT begins. The current recruitment status is unclear.

Study design

This is an interventional study with a planned enrollment of 46 participants. It is not specified if it is randomized or blinded.

What's involved

Participants will receive SBRT to a single metastatic site while continuing their usual drug therapy. SBRT will be given over 3 or 5 daily sessions, excluding weekends and holidays.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed to measure progression-free survival at 3 months from the start of SBRT delivery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.